• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, June 14, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Systemic sclerosis-associated interstitial lung disease focus of latest clinical practice guideline

Bioengineer by Bioengineer
November 8, 2023
in Health
Reading Time: 2 mins read
0
ADVERTISEMENT
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

In patients with systemic sclerosis (SSc), a rare connective tissue disease, interstitial lung disease contributes to 35 percent of deaths. Published recently in the American Journal of Respiratory and Critical Care Medicine, the latest American Thoracic Society Clinical Practice Guideline makes a number of recommendations. One recommendation expands antifibrotic treatment to all patients with systemic sclerosis associated with ILD (SSc-ILD), not just those with progressive disease.

Clinical Practice Guideline

Credit: ATS

In patients with systemic sclerosis (SSc), a rare connective tissue disease, interstitial lung disease contributes to 35 percent of deaths. Published recently in the American Journal of Respiratory and Critical Care Medicine, the latest American Thoracic Society Clinical Practice Guideline makes a number of recommendations. One recommendation expands antifibrotic treatment to all patients with systemic sclerosis associated with ILD (SSc-ILD), not just those with progressive disease.

Watch the explainer video.

Lead guidelines chair and editor, Ganesh Raghu, M.D., ATSF, noted the timeliness of the recommendations given the many immune modulating agents clinicians already use to treat connective tissue diseases, including SSc. “The need to provide evidence-based clinical practice guideline was evident,” he said.

It was with this in mind that the 24-member international expert panel (that included pulmonologists, rheumatologists, methodologists and patients with SSc) convened. Using the thorough, evidence-based Grading of Recommendations, Assessment, Development and Evaluation or GRADE framework, the expert panel made the following recommendations and suggestions for treating patients with SSc-ILD:

1.We recommend using mycophenolate to treat patients with SSc-ILD (strong recommendation, very low-quality evidence).

 

2.We suggest using the following medications to treat patients with SSc-ILD:

i :   cyclophosphamide (conditional recommendation, low- quality evidence).

ii :  nintedanib  (conditional recommendation, very low-quality evidence).

iii:   rituximab  (conditional recommendation, very low-quality evidence).

iv:   tocilizumab  (conditional recommendation, very low-quality evidence).

v:   the combination of nintedanib plus mycophenolate (conditional recommendation, very low-quality evidence).

 

3. We recommend further research into the safety and efficacy of pirfenidone  alone or in combination with mycophenolate  to treat patients with SSc-ILD.

Regarding treatment with antifibrotics like nintedanib and pirfenidone, “We emphasize the importance of the shared decision process with patients and physicians, especially for the recommendations that are conditional,” added Dr. Raghu.

To read the latest clinical practice guideline on systemic sclerosis-associated interstitial lung disease in its entirety, visit us online.

For ATS guideline implementation tools and derivatives, go here.
 

To learn about clinical trials recruiting patients with SSc-ILD, visit the ATS Clinical Trials Resources page. *The ATS does not endorse any trial listed.

 



Journal

American Journal of Respiratory and Critical Care Medicine

Method of Research

Systematic review

Subject of Research

People

Article Title

Treatment of Systemic Sclerosis-associated Interstitial Lung Disease: Evidence-based Recommendations. An Official American Thoracic Society Clinical Practice Guideline

Share12Tweet8Share2ShareShareShare2

Related Posts

Rewrite Excitation-inhibition balance abnormally shapes structure–function coupling of gray matter in Parkinson’s disease as a headline for a science magazine post, using no more than 8 words

Rewrite Excitation-inhibition balance abnormally shapes structure–function coupling of gray matter in Parkinson’s disease as a headline for a science magazine post, using no more than 8 words

June 13, 2025
Rewrite Repurposing the memory-promoting meclofenoxate hydrochloride as a treatment for Parkinson’s disease through integrative multi-omics analysis as a headline for a science magazine post, using no more than 8 words

Rewrite Repurposing the memory-promoting meclofenoxate hydrochloride as a treatment for Parkinson’s disease through integrative multi-omics analysis as a headline for a science magazine post, using no more than 8 words

June 13, 2025

Rewrite Myelin–axon interface vulnerability in Alzheimer’s disease revealed by subcellular proteomics and imaging of human and mouse brain as a headline for a science magazine post, using no more than 8 words

June 13, 2025

Rewrite The role and mechanism of fatty acid oxidation in cancer drug resistance as a headline for a science magazine post, using no more than 8 words

June 13, 2025

POPULAR NEWS

  • Green brake lights in the front could reduce accidents

    Study from TU Graz Reveals Front Brake Lights Could Drastically Diminish Road Accident Rates

    158 shares
    Share 63 Tweet 40
  • New Study Uncovers Unexpected Side Effects of High-Dose Radiation Therapy

    75 shares
    Share 30 Tweet 19
  • Pancreatic Cancer Vaccines Eradicate Disease in Preclinical Studies

    68 shares
    Share 27 Tweet 17
  • How Scientists Unraveled the Mystery Behind the Gigantic Size of Extinct Ground Sloths—and What Led to Their Demise

    64 shares
    Share 26 Tweet 16

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Rewrite Two frontiers: Illinois experts combine forces to develop novel nanopore sensing platform this news headline for the science magazine post

Rewrite Review of active distribution network reconfiguration: Past progress and future directions this news headline for the science magazine post

Rewrite University of Cincinnati structural biology research published in prestigious PNAS this news headline for the science magazine post

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.